J2h Biotech
Clinical trials sponsored by J2h Biotech, explained in plain language.
-
First human test for fatty liver pill shows path forward
Disease control CompletedThis early-stage study tested a new oral drug called J2H-1702, which is being developed to treat non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The main goal was to check the drug's safety, how the body processes it, and how well it was tolerated in …
Phase: PHASE1 • Sponsor: J2H Biotech • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New drug shows promise in early trial for serious fatty liver disease
Disease control CompletedThis study tested a new drug called J2H-1702 for people with non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. 87 participants received either one of three doses of the drug or a placebo for 12 weeks. The main goals were to check the drug's safety and s…
Phase: PHASE2 • Sponsor: J2H Biotech • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC
-
First step: new liver disease drug tested for safety in small group
Knowledge-focused CompletedThis was a very early, first-in-human study to see if a single dose of a potential new medicine called J2H-1702 is safe for people. It involved 16 healthy female volunteers to check for side effects and measure how the drug moves through the body. The goal was to gather basic saf…
Phase: PHASE1 • Sponsor: J2H Biotech • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:24 UTC